AS Latvijas Juras medicinas centrs (ORSE:LJM1R) PE Ratio: 26.09 (As of Jul. 12, 2026) — 40% Above Median


ORSE:LJM1R AS Latvijas Juras medicinas centrs ORSE:LJM1R
59 GF Score
Price €7.80
GF Value €7.78
! 3 Warning Signs
View Full Analysis

What is AS Latvijas Juras medicinas centrs PE Ratio?

AS Latvijas Juras medicinas centrs ORSE:LJM1R 59 PE Ratio is 26.09 as of Jul. 12, 2026, which is 40% above its 10-year median of 18.58. GuruFocus rates ORSE:LJM1R with a GF Score™ of 59/100 and a GF Value™ of €7.78. The stock has 3 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-12), AS Latvijas Juras medicinas centrs's share price is €7.80. AS Latvijas Juras medicinas centrs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.30. Therefore, AS Latvijas Juras medicinas centrs's PE Ratio for today is 26.09.

During the past 13 years, AS Latvijas Juras medicinas centrs's highest PE Ratio was 212.55. The lowest was 4.91. And the median was 18.58.

AS Latvijas Juras medicinas centrs's EPS (Diluted) for the three months ended in Dec. 2025 was €0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.30.

As of today (2026-07-12), AS Latvijas Juras medicinas centrs's share price is €7.80. AS Latvijas Juras medicinas centrs's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €0.30. Therefore, AS Latvijas Juras medicinas centrs's PE Ratio without NRI ratio for today is 26.09.

During the past 13 years, AS Latvijas Juras medicinas centrs's highest PE Ratio without NRI was 208.13. The lowest was 5.15. And the median was 18.58.

AS Latvijas Juras medicinas centrs's EPS without NRI for the three months ended in Dec. 2025 was €0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €0.30.

During the past 12 months, AS Latvijas Juras medicinas centrs's average EPS without NRI Growth Rate was 30.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was -27.30% per year.

During the past 13 years, AS Latvijas Juras medicinas centrs's highest 3-Year average EPS without NRI Growth Rate was 54.90% per year. The lowest was -40.60% per year. And the median was -20.05% per year.

AS Latvijas Juras medicinas centrs's EPS (Basic) for the three months ended in Dec. 2025 was €0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.30.

Back to Basics: PE Ratio


AS Latvijas Juras medicinas centrs  (ORSE:LJM1R) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


AS Latvijas Juras medicinas centrs PE Ratio Related Terms


AS Latvijas Juras medicinas centrs PE Ratio Historical Data

* Premium members only.

The historical data trend for AS Latvijas Juras medicinas centrs's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AS Latvijas Juras medicinas centrs PE Ratio Chart

AS Latvijas Juras medicinas centrs Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.64 15.00 At Loss 28.26 29.67

AS Latvijas Juras medicinas centrs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.26 41.06 20.00 10.88 29.67

ORSE:LJM1R vs HCA, THC, ENSG: PE Ratio Comparison

For the Medical Care Facilities subindustry, AS Latvijas Juras medicinas centrs's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AS Latvijas Juras medicinas centrs PE Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, AS Latvijas Juras medicinas centrs's PE Ratio distribution charts can be found below:

* The bar in red indicates where AS Latvijas Juras medicinas centrs's PE Ratio falls into.


ORSE:LJM1R
59GF Score
AS Latvijas Juras medicinas centrs ORSE:LJM1R
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AS Latvijas Juras medicinas centrs PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

AS Latvijas Juras medicinas centrs's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=7.80/0.299
=26.09

AS Latvijas Juras medicinas centrs's Share Price of today is €7.80.
AS Latvijas Juras medicinas centrs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.30.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 26.09 mean?
AS Latvijas Juras medicinas centrs (ORSE:LJM1R) has a PE Ratio of 26.09 as of Jul. 12, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on AS Latvijas Juras medicinas centrs and its competitors. This is 40% above median its historical median of 18.58. Over the past decade, AS Latvijas Juras medicinas centrs' PE Ratio has ranged from 4.91 to 212.55.
Is AS Latvijas Juras medicinas centrs' PE Ratio too high?
AS Latvijas Juras medicinas centrs' current PE Ratio of 26.09 is 40% above median its 10-year median of 18.58. Over the past 10 years, this metric has ranged from a low of 4.91 to a high of 212.55. Overall, AS Latvijas Juras medicinas centrs has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does AS Latvijas Juras medicinas centrs' PE Ratio compare to HCA and THC?
AS Latvijas Juras medicinas centrs' PE Ratio of 26.09 can be compared against companies in the Healthcare Providers & Services industry. Historically, AS Latvijas Juras medicinas centrs' own PE Ratio has ranged from 4.91 to 212.55 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Healthcare Providers & Services company?
A good PE Ratio depends on the Healthcare Providers & Services industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on AS Latvijas Juras medicinas centrs and its competitors. AS Latvijas Juras medicinas centrs's current PE Ratio is 26.09, which is 40% above median its own 10-year median of 18.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AS Latvijas Juras medicinas centrs stock overvalued right now?
AS Latvijas Juras medicinas centrs (ORSE:LJM1R) has a current PE Ratio of 26.09. The stock's GF Value™ is €7.78, compared to a current price of €7.80 — trading 0.3% above its estimated fair value. The current PE Ratio is 26.09, which is 40% above median its 10-year median of 18.58. AS Latvijas Juras medicinas centrs' overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For AS Latvijas Juras medicinas centrs (ORSE:LJM1R), the current PE Ratio is 26.09 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AS Latvijas Juras medicinas centrs (ORSE:LJM1R) Overvalued in 2026?

Based on GuruFocus' analysis, AS Latvijas Juras medicinas centrs stock appears to be overvalued. The current stock price of €7.80 is trading 0.3% above its estimated GF Value™ of €7.78.

Key valuation signals for ORSE:LJM1R:

  • PE Ratio: 26.09 (40% above median its 10-year median of 18.58)
  • GF Value™: €7.78 vs. price of €7.80 (0.3% above fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the ORSE:LJM1R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AS Latvijas Juras medicinas centrs Business Description

Address Patversmes iela 23, Riga, LVA, LV-1005
AS Latvijas Juras medicinas centrs is a private certified medical institution in Latvia providing outpatient and inpatient healthcare services through qualified staff and modern equipment. Its core activities include hospital services, orthopaedic retail, medical and dental practice, human health and residential care, social work activities, and physical well-being services. It operates the Women's Health Clinic, offering gynecological consultations, pregnancy care, diagnostics, postpartum services, gynecological care for girls, and surgery. The centre also provides vaccination, rehabilitation, a Multiple Sclerosis Center, medical commission, home visits, laboratory services, physical medicine and massage, therapeutic procedures, medical treatment, and anesthesia and intensive care.
59GF Score

Get the complete analysis for ORSE:LJM1R

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.80
Price
€7.78
GF Value